Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and ArchiveĀ 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-48014

Zardavas , D; Meisel , A; Samaras , P; Knuth , A; Renner , C; Pestalozzi , B C; Stenner-Liewen , F (2011). Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. Case Reports in Oncology, 4(1):16-18.

[img]
Preview
Published Version
PDF
1444Kb
[img]Supplemental Material
Video (AVI) (Video 1)
12Mb
[img]Supplemental Material
Video (AVI) (Video 2)
13Mb

Abstract

We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. After failure of two sequentially administered tyrosine kinase inhibitors, treatment with temsirolimus resulted in a prolonged partial remission of 14 months, and the response is still continuing. Up to now, no data from randomized clinical studies have been published addressing the question of efficacy of temsirolimus as third-line treatment after failure of tyrosine kinase inhibitors. The case presented here implies that temsirolimus could be a viable option for patients with metastatic chromophobe renal cell carcinoma.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology
DDC:610 Medicine & health
Language:English
Date:2011
Deposited On:06 May 2011 13:15
Last Modified:23 Nov 2012 15:45
Publisher:Karger
ISSN:1662-6575
Publisher DOI:10.1159/000323804
PubMed ID:21526001
Citations:Google Scholarā„¢

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page